Insulet (NASDAQ:PODD) Earns “Outperform” Rating from Svb Leerink

Svb Leerink reiterated their outperform rating on shares of Insulet (NASDAQ:PODD) in a research report report published on Wednesday morning, Zacks.com reports.

Several other research analysts also recently commented on PODD. BTIG Research raised their price target on shares of Paypal from $114.00 to $130.00 and gave the stock a buy rating in a research note on Monday, May 6th. They noted that the move was a valuation call. Canaccord Genuity reduced their price target on shares of Jamieson Wellness from C$23.00 to C$20.00 in a research note on Monday, May 6th. JPMorgan Chase & Co. downgraded shares of Sogou from a neutral rating to an underweight rating and reduced their price target for the stock from $5.50 to $4.12 in a research note on Thursday, June 27th. ValuEngine downgraded shares of Virtu Financial from a hold rating to a sell rating in a research note on Tuesday, June 18th. Finally, UBS Group set a €110.00 ($127.91) price target on shares of Wacker Chemie and gave the stock a buy rating in a research note on Thursday, June 13th. Five analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Insulet has an average rating of Buy and a consensus price target of $110.09.

Shares of PODD opened at $120.25 on Wednesday. Insulet has a twelve month low of $70.80 and a twelve month high of $124.38. The stock has a market capitalization of $7.39 billion, a P/E ratio of 2,405.00 and a beta of 1.12. The company has a current ratio of 4.36, a quick ratio of 3.71 and a debt-to-equity ratio of 2.68. The company has a fifty day moving average price of $115.35.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.05. The business had revenue of $159.56 million for the quarter, compared to the consensus estimate of $154.66 million. Insulet had a net margin of 2.37% and a return on equity of 7.01%. The business’s revenue for the quarter was up 29.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. As a group, sell-side analysts forecast that Insulet will post 0.27 EPS for the current year.

In other Insulet news, COO Charles Alpuche sold 3,900 shares of the stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $104.78, for a total transaction of $408,642.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David A. Lemoine sold 8,752 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $106.92, for a total transaction of $935,763.84. Following the transaction, the director now owns 9,148 shares in the company, valued at $978,104.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,894 shares of company stock worth $4,524,025. 3.50% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the business. Stephens Investment Management Group LLC grew its holdings in Insulet by 19.6% during the 1st quarter. Stephens Investment Management Group LLC now owns 129,239 shares of the medical instruments supplier’s stock worth $12,289,000 after acquiring an additional 21,206 shares in the last quarter. California State Teachers Retirement System grew its holdings in Insulet by 2.3% during the 4th quarter. California State Teachers Retirement System now owns 91,965 shares of the medical instruments supplier’s stock worth $7,295,000 after acquiring an additional 2,073 shares in the last quarter. C WorldWide Group Holding A S grew its holdings in Insulet by 102.6% during the 1st quarter. C WorldWide Group Holding A S now owns 52,672 shares of the medical instruments supplier’s stock worth $5,009,000 after acquiring an additional 26,678 shares in the last quarter. Oak Ridge Investments LLC grew its holdings in Insulet by 4.0% during the 1st quarter. Oak Ridge Investments LLC now owns 119,497 shares of the medical instruments supplier’s stock worth $11,363,000 after acquiring an additional 4,648 shares in the last quarter. Finally, Amalgamated Bank grew its holdings in Insulet by 63.2% during the 4th quarter. Amalgamated Bank now owns 13,059 shares of the medical instruments supplier’s stock worth $1,036,000 after acquiring an additional 5,055 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Read More: Why are gap-down stocks important?

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.